Researchers from University of Michigan presented preclinical data for the novel oxylipin analogue CS-585 being developed as an antithrombotic agent. CS-585 was synthesized as an orally available analogue of 12(S)-hydroxy-eicosatrienoic (12-HETrE), with potent and selective prostacyclin (IP) receptor agonist activity and ability.
A Spanish study led by scientists from the Cajal Institute and the National Center of Oncological Research (CNIO) combined the power of artificial neural networks and biological neuronal circuits to identify abnormal brain activity produced by secondary metastases in the CNS and classify these tumors. The work, published online on Aug. 30, 2023, in Cancer Cell, showed how damage in the brain did not depend on the tumor size but on the effect it produced on neuronal circuits, interrupting cell communication.
Purdue Research Foundation has prepared and tested new peptides acting as N-terminal Xaa-Pro-Lys N-methyltransferase 1 (NTMT1) inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented imidazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists. They are reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and ocular disorders.
Research at Aurigene Oncology Ltd. has led to the identification of fused bicyclic heterocyclyl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer.
A DE Shaw Research LLC patent reports N3-substituted uracil compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists. As such, they are reported to be useful for the treatment of pain, fibrosis, autoimmune disease, neurological, dermatological, cardiovascular, respiratory and gastrointestinal disorders, among others.
Wistar Institute of Anatomy & Biology has synthesized new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors for the treatment of SARS-CoV-2 infection (COVID-19).
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate immunity by acting both as a scaffolding protein and a protein kinase, and its overactivation correlates with several autoimmune disorders.
Researchers from Guangdong Pharmaceutical University and affiliated organizations have discovered novel farnesoid X receptor (FXR) agonists as candidates for the treatment of nonalcoholic steatohepatitis (NASH).
RSS
